Abstract 94P
Background
Soft-tissue sarcomas arise from connective tissues and account for <1% of all adult tumors. Retroperitoneal sarcomas are a subtype representing <12% of all sarcomatous tumors with incidence of 2.7 per million. The evaluation and management of retroperitoneal sarcoma is challenging due to its scarcity and silent progression. The current standard treatment is primary surgical resection but there are no standards for the addition of systemic therapy. As adjuvant radiotherapy and adjuvant chemotherapy remains controversial, our aim was to provide additional evidence about systemic therapy impact after surgical resection for retroperitoneal soft tissue sarcomas.
Methods
Data of 2595 patient was extracted with Surveillance, Epidemiology and End Results (SEER) program software, all of them were diagnosed with retroperitoneal soft tissue sarcoma from 2000-2019. All patients had surgical resection of the tumor but the 1st group received adjuvant chemotherapy, the 2nd group received adjuvant radiotherapy and the 3rd group received no systemic therapy. We used SPSS for data analysis, Kaplan-Meier curve and Log-rank test for survival analysis.
Results
The 3-year and 5-year overall relative survival for retroperitoneal soft tissue sarcoma were 71% and 62% with mean age of 59.7. Adjuvant radiotherapy had similar 5-year relative survival outcome compared to surgical resection with no systemic therapy, while both had survival benefit of 32% from adjuvant chemotherapy which had the worst survival outcome (64.7%, 65.9% and 33.9%, respectively; P>0.001). Performing COX-regression model, age and sex were strongly associated with survival outcome (P>0.001) while race was a weak prognostic factor (P=0.23).
Conclusions
These results clarify that the standard surgical resection can be the first-line treatment with no survival benefit from adding adjuvant chemo(radio)therapy so leading the avoidance of unnecessary complications of chemotherapy and radiation and improvement patients' quality of life after treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.